The protocol, tested as part of a clinical study conducted by the biotechnology company Cellprothera, currently concerns about fifteen patients in France, including three in Burgundy. “We will be able to include about fifteen patients per year”, specifies Professor Yves Cottin, head of the cardiology service, who relies in particular on the Nevers hospital center to refer patients to him.
A new interim director at the Nevers hospital center
The treatment consists, by “simple blood test”, to take stem cells (CD 34) from the patient to put them in culture (for nine days) before reinjecting them “into the wall of the necrotic heart”, explains the patient. cardiologist. This represents, according to the patients, between 10 and 50 million stem cells which are reinjected to colonize the area which can contain up to 2 billion dead cells.
He has already recovered when, after such an attack, he would be in heart failure, with difficulty climbing stairs. He has none of that. It’s a real success!
–
Two billion dead cells: that’s huge. The treatment, in fact, targets “patients who have had a severe infarction” and who, because a large part of the heart is necrotic, “will not recover”, specifies Yves Cottin. This represents “10% of infarcts” or, for the Nièvre “,” about 50 cases per year “, he says.
The first patient received an injection in Dijon on February 5. “I saw him in consultation eight days ago,” said Professor Cottin. He has already recovered when, after such an attack, he would be in heart failure, with difficulty climbing stairs. He has none of that. It’s a real success! “
The treatment, if it obtains the marketing authorization, “will offer a new path between pharmacological treatment, cardiac assistance and transplant”. One of the major advantages: there can be no rejection since “it is the cells of the patient” himself which give him the capacity to “repair itself”.
– .
